Related Experiment Video
Updated: Jun 1, 2026

Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Refractory vasculitis
Abraham Rutgers1, Cees G M Kallenberg
1University Medical Center Groningen (UMCG), University of Groningen, Department of Rheumatology en Clinical Immunology, The Netherlands. a.rutgers@reuma.umcg.nl
Abstract:
Refractory vasculitis occurs in 4-5% of patients with anti-neutrophil cytoplasmic antibody associated vasculitis (AAV). Differences between therapies used for refractory disease are mostly reflected in the percentages of complete and partial remissions, but also in the number of serious side effects. Rituximab is considered the most safe second line therapy and should be advocated as a first alternative choice for cyclophosphamide in disease induction in refractory AAV.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy
Continuous Renal Replacement Therapy
Vascular Spasm
Diabetic Retinopathy
Varicose Veins II: Diagnostic Studies and Interprofessional Care
